Outlook Therapeutics
OTLK
81 hedge funds and large institutions have $6.11M invested in Outlook Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 18 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
0.04% less ownership
Funds ownership: 0.57% → 0.53% (-0.04%)
7% less funds holding
Funds holding: 87 → 81 (-6)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
88% less capital invested
Capital invested by funds: $51.1M → $6.11M (-$45M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$533K |
| 2 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$303K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$287K |
| 4 |
BlackRock
New York
|
+$196K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$3.02M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$1.04M |
| 3 |
Squarepoint
New York
|
-$551K |
| 4 |
Millennium Management
New York
|
-$250K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$191K |
OTLK Hedge Fund Activity: Q3 2023 in Review
81 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2023, worth a combined $6.11M — down 88% from $51.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of OTLK and 13 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 25 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $533K. The largest seller was LVW Advisors, exiting entirely with an estimated $3.02M sold.
- 81 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2023, down from 87 in Q2 2023.
- Funds reported $6.11M of Outlook Therapeutics stock for Q3 2023, down 88% quarter-over-quarter.
- 13 funds opened new Outlook Therapeutics positions in Q3 2023 and 18 closed out, a net change of -5 holders.
- The largest Outlook Therapeutics buyer in Q3 2023 was BNP Paribas Financial Markets, an estimated $533K added.
- The largest Outlook Therapeutics seller in Q3 2023 was LVW Advisors, an estimated $3.02M sold.
Based on aggregated 13F filings for Q3 2023.